Daiwa Health Development, Inc. is the U.S. subsidiary of Daiwa Pharmaceutical Co. Ltd. The parent company based in Tokyo, Japan, has become a leading research and manufacturing company. Striving to create new value in the field of bioscience, Daiwa focuses on the manufacturing and distribution of neutraceuticals, functional foods and cosmetics. Founded in 1990, Daiwa Pharmaceutical provides products and distribution to 27 countries.
A core neutraceutical from Daiwa is Biobran MGN-3, a unique immune modulator, derived from rice bran. Biobran MGN-3 has become the gold standard immune product, worldwide, for people with seriously compromised immune systems. PeakImmune4 is the brand name for the product in the US. It is a dietary supplement for strengthening the immune system.
The company has created an international Intelligence Network that draws upon some of the most respected researchers at leading organizations and institutions. Collaborative partnerships with institutions such as Chibu University and Nagoya University (Japan), University of California Los Angeles (UCLA) and DREW University of Medicine and Science (USA), Oxford University and Cambridge University (UK) and Groningen University (Netherlands), as well as research relationships with Japanese ministry bodies including the Ministry of Agriculture, Forestry and Fisheries of Japan, have strengthened the companys ability to provide Evidence Based Medicines worldwide.
Daiwa believes it is of the utmost importance to trust in nature, with which we must coexist. It also believes that the body's natural healing power provides the foundation necessary to improve our physical condition. This premise represents the basic principle for the origin of business for Daiwa Pharmaceutical Co., Ltd, and Daiwa Health Development.